UPC Milan division upholds Lundbeck pharma patent over Biogaran challenge

The Unified Patent Court's Milan section rejected Biogaran's revocation action against Lundbeck's EP 4 223 296, a signal on how patient-subgroup pharmaceutical claims survive European validity challenges.